PD-1 blockade has demonstrated remarkable clinical efficacy across various tumor types. However, primary or acquired resistance eventually leads to cancer progression in clinical settings. Understanding the underlying mechanisms of resistance is both necessary and urgent to enhance clinical outcomes. At AACR 2024, WuXi AppTec presented a poster describing the development of two types of anti-PD-1 …Read More >

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated through CAR-T, leading to the inhibition of CAR-T cell activity via the PD-1 pathway.  At AACR 2024, WuXi AppTec presented a poster describing an engineered CAR-T therapy that targets mesothelin and concurrently expresses a membrane-bound …Read More >

Despite the success of delivery technologies such as lipid nanoparticles and trivalent GalNAc conjugation, targeted delivery of oligonucleotides to extra hepatic tissues remains a challenge.  At this year’s OPT Congress, WuXi AppTec presented a poster showing the utilization of our peptide-based DNA-encoded library screening platform to identify endocytosis receptor-binding peptides.  The binding affinity of hit …Read More >

Fragment-based drug discovery (FBDD) is one of the most well-developed approaches for projects starting from small, low-affinity compounds.  At the SLAS 2024 meeting in Boston, WuXi AppTec presented a poster reporting on the assembly of a covalent fragment library that is suited to tackle protein targets via serine, lysine, and cysteine residues. In a case …Read More >

Despite improvement in clinical outcomes observed with the use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs), long-term prognosis remains unfavorable due to the development of either intrinsic or acquired resistance.  Understanding the mechanisms underlying this resistance is vital for designing strategies to address this challenge, and one approach involves the establishment of …Read More >

SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished from conventional protein-targeted therapy, nucleic acid therapeutics offer the potential for sustained effects via gene modification or inhibition. In this study, we conducted a comprehensive evaluation of the activity and anti-tumor effects of PKN3-targeted siRNA …Read More >

SITC Poster #452: Alopecia areata (AA) is an autoimmune disease characterized by patchy and sudden hair loss without scarring, resulting in a heavy psychological burden on patients. To better understand the pathogenesis and treatment of alopecia areata, we developed a skin grafts-induced alopecia areata model to provide a reproducible, reliable animal model for AA research. …Read More >

SITC Poster #446: Inflammatory bowel disease (IBD) is recognized as an autoimmune disorder characterized by chronic inflammation of the digestive tract. The pathogenesis of IBD is not fully understood and can repeatedly relapse despite clinical therapy. The T cell transfer-induced colitis model enables the study of early inflammation and immunological responses in the colon, such …Read More >

SITC Poster #1162: Enhertu is currently approved for the treatment of patients with HER2-positive breast cancer, gastric cancer, or HER2-mutant non-small cell lung cancer. However, despite Enhertu’s clinical benefits, most patients inevitably experience disease progression and mortality. Understanding drug resistance mechanisms can aid in developing new treatment strategies for drug-resistant clinical patients. In this study, …Read More >